Gate2Brain receives €2.5M through the EIC Accelerator programme
Gate2Brain -a spin-off from the Institute for Research in Biomedicine (IRB Barcelona), the University of Barcelona (UB) and the Sant Joan de Déu Research Institute (IRSJD)- Hospital Sant Joan de Déu (SJD)- receives €2.5m funding from the EIC Accelerator programme to boost the preclinical regulatory studies of their drug G2B-00, which is targeted at the brain tumors with intact barriers. In two or three years, these results will open the doors to a clinical trial.
Gate2Brain has a patented technology based on peptides (small proteins) that efficiently cross biological barriers, such as the blood-brain barrier that protects the brain. As if they were molecular shuttles, these peptides can carry drugs that unaided cannot reach the brain to cure it. The first indication that will benefit from the technology is in the field of pediatric brain tumors.
“Man has dreamed of traveling to the brain for decades and, in fact, science fiction has dedicated books and films such as Isaac Asimov’s Fantastic Voyage. Gate2Brain’s dream is to improve the health and quality of life of people suffering from central nervous system diseases by improving drug delivery to the brain and treating it”, says Dr. Meritxell Teixidó, CEO of Gate2Brain. She also adds that “today, just before Christmas, that dream is one step closer thanks to funding from the EIC Accelerator.”